Merck's Gardasil sales decline due to weak demand trends in China, with new launches expected to offset the downside.

I use option collars on struggling stocks like Merck & Co., Inc. to cap downside risk while maintaining upside potential, especially when the technicals look uncertain. My MRK collar trade earlier ...

MRK wins early FDA approval for RSV antibody Enflonsia in infants, with U.S. launch planned before the 2025-26 season.

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Positive Topline Results from Phase 3 CORALreef Trials Evaluating Enlicitide Decanoate for the Treatment of Adults with Hyperlipidemia.

Merck's (NYSE:MRK) top-selling drug – Keytruda's – impressive recent growth tells a compelling story, but it's one with a predictable ending. The pharmaceutical giant's remarkable performance is la...

Despite a catastrophic drop in sales of the Gardasil franchise, mainly due to weak demand from China, Merck once again beat consensus EPS and revenue estimates. So, the key contributors whose perfo...

Merck stock lags industry as Keytruda dependency, Gardasil woes in China, and tariff risks cloud outlook despite pipeline strength and new launches.

Merck (NYSE:MRK) stock has experienced a significant 22% decline this year, sharply underperforming the broader S&P 500 index, which is down only 1%. This downturn can be attributed to several fact...

The market has largely priced in the 2028 Keytruda patent cliff, with Merck trading at a discount reflecting aggressive revenue erosion assumptions. Merck is actively expanding in oncology, immunol...

DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced the presentation of new oncology data across more than 12 tumor types at the 2025 American Soci...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the Bernstein 41st Annual Strategic Decisions Conference.

RAHWAY, N.J.--(BUSINESS WIRE)--Merck Breaks Ground on New $1 billion Biologics Center of Excellence in Wilmington, Delaware.

U.S. drugmaker Merck is investing $1 billion in a new Delaware plant to expand its domestic production as it prepares to deal with the looming impact from President Donald Trump's tariffs, the Wall...

We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors may exit the stock.

– Purchase price of $47 per share in cash represents an equity value of approximately $3.9 billion, or an enterprise value of $3.4 billion (€3.0 billion) – – Planned acquisition will immediately ad...